生物测定
生化工程
药物发现
药物开发
质量(理念)
生物技术
计算机科学
计算生物学
风险分析(工程)
生物
工程类
业务
药理学
生物信息学
药品
生态学
哲学
认识论
作者
John R. White,Marla Abodeely,Sammina Ahmed,Gaël Debauve,Evan Johnson,Debra M. Meyer,Ned M. Mozier,Matthias Naumer,Alessandra Pepe,Isam Qahwash,Edward Rocnik,Jeffrey G. Smith,Elaine S. E. Stokes,Jeffrey J. Talbot,Pin Yee Wong
出处
期刊:BioTechniques
[Future Science Ltd]
日期:2019-08-05
卷期号:67 (3): 126-137
被引量:29
标识
DOI:10.2144/btn-2019-0031
摘要
Biological activity is a critical quality attribute for biopharmaceuticals, which is accurately measured using an appropriate relative potency bioassay. Developing a bioassay is a complex, rigorous undertaking that needs to address several challenges including modelling all of the mechanisms of action associated with the biotherapeutic. Bioassay development is also an exciting and fast evolving field, not only from a scientific, medical and technological point of view, but also in terms of statistical approaches and regulatory expectations. This has led to an industry-wide discussion on the most appropriate ways to develop, validate and control the bioassays throughout the drug lifecycle.
科研通智能强力驱动
Strongly Powered by AbleSci AI